SSRI Advisory Committee
This article was originally published in The Pink Sheet Daily
FDA "has not yet made a final determination on the need for an advisory board on suicidality in adults" using selective serotonin reuptake inhibitors, Johnson & Johnson says
You may also be interested in...
A committee will meet within the next few months to review selective serotonin reuptake inhibitors and suicidality in adults, J&J Senior VP Waldstreicher says. The company’s NDA for the SSRI dapoxetine is pending; J&J is seeking to differentiate the premature ejaculation agent from the rest of the class.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.